Are you above the legal age to view this content in your province/state?

Home / Industry News / An Israeli company was granted a license to import and commercialize medical marijuana

An Israeli company was granted a license to import and commercialize medical marijuana

An Israeli company was granted a license to import and commercialize medical marijuana

U.S, July 24, 2019 (MARIJUANA BUSINESS DAILY)- An Israeli company was granted a license to import and commercialize medical marijuana, marking an industry first in a country that expects cannabis exports to be an economic driver for the sector.

However, the country is yet to see its first commercial medical cannabis export, despite the approval of  law about six months ago.

Tel Aviv-based Syqe Medical told Marijuana Business Daily it “has been granted a license from the Israeli Ministry of Health for the import and commercialization of medical cannabis.”

Medical cannabis from Bedrocan in the Netherlands is being used in the Syqe Inhaler, which was launched in Israel last month.While imports have occurred for research and development for years, this is thought to be the first authorized commercial import.

The inhaler, which delivers a consistent, selected, noncombustable dosage, is being sold in Israel by Teva.

The company is already looking for a local supplier, suggesting the imports may not last long.

“Syqe is in discussions with Israeli growers, and we look forward to working with them in the near future,” a company spokesperson said.

Syqe is also “exploring opportunities” with distributors and regulators to launch the product in other countries.

In a statement to MJBizDaily, the Israeli Ministry of Health noted that regulations in effect already empower the agency to approve medical cannabis imports for both research and development and commercial purposes:

“Importation of medical cannabis is possible according to the GMP and other requirements, both for research as well as medical indications.”

The country currently has 46,000 registered patients.

The import approval comes as Israel’s medical cannabis exports face further delays.

For years, companies in Israel have been gearing up for local and international shipments, often with investments underwritten by international players.

Lilac Mandeles, CEO of TechForCann, said some local growers were surprised by the import approval given that exports are not effectively happening yet.

“Now there is a concern among the growers from outside competition,” she said.

Local experts said there could be opportunities for international companies to meet demand in Israel.

Michael Dor, former senior medical adviser to the Israeli Ministry of Health’s Medical Cannabis Unit, said high domestic prices force some patients to the illicit market but also create “an opportunity for foreign companies to import cannabis to Israel.”

“It is very difficult to predict the governmental policy about import,” he said, “but I assume that there will be a tendency to open the market for competition, and Israeli producers will focus on new products and medications.”


Investment Value Finders specializes in providing opinions and information on stocks to individuals who wish to receive them. Our reports are construed for information purposes solely and are distributed free of charge to individuals who wish to receive them.

Investment Value Finders does not promote, condone or advocate licit or illicit drug use. Investment Value Finders cannot be held responsible for materials or contests posted on its website pages, or pages to which we provide links, which promote, condone or advocate licit or illicit drug use or illegal activities.

DO NOT BASE ANY INVESTMENT DECISION UPON ANY MATERIALS FOUND ON THIS WEBSITE. We are not registered as a securities broker-dealer or an investment adviser. We are neither licensed nor qualified to provide investment advice.

Investment Value Finders occasionally receives direct compensation for hosting links (or other* advertisements) to third party content that may be subject to disclaimer pursuant to Section 17(b) of the Securities Act of 1933. For those instances where the link text contains company or stock-specific mention, we provide the following list of compensation received in order to ensure full disclosure and transparency.

Investment Value Finders is intended for those 21+ years of age only!

Check Also

Stocks and Founds that are overexposed To Russia And Ukraine

Stock markets worldwide have been in red since Russia began its invasion of Ukraine last …